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Multiple sclerosis (MS) is an inflammatory disorder of the
central nervous system (CNS) and is the most com-
mon cause of neurological disability in young adults.
MS-Associated Retrovirus (MSRV) is member of Human
Endogenous Retroviruses W family, and their increased
activity in MS patients is associated to the disease immu-
nopathogenesis. Natalizumab, an antibody-based therapy,
hinders migration of T cells into the CNS and is currently
the most potent treatment for MS. Although Natalizumab
interferes with gene expression relevant for function and
differentiation of lymphocytes, its effects on genes involved
in immunopathogenesis are unknown. Here, we report the
effect of different treatments on the HERV-W/MRSV
expression in patients with relapsing-remitting MS. MRSV
transcripts were quantified by qRT-PCR in peripheral
blood mononuclear cells of 9 patients receiving Natalizu-
mab for at least 6 months (MSNat group) and 11 patients
under immunosuppressive treatments (MSI group). The
mean age was 28 years (18-35) for MSNat group and 44
(28-54) for MSI. The mean Expanded Disability Status
Scale (EDSS) score was 4 (2-6) and 2.6 (1-6.5) for MSNat
and MSI groups respectively. MSRV transcripts level was
slightly higher in MSNat group, although not significantly,
suggesting that Natalizumab does not interfere on HERV-
W expression. Patients included in Natalizumab protocol
usually do not respond to other treatments and present
higher EDSSs. Possibly, EDSS and age have more impact
in retroelements activity, as already demonstrated. This is
the first comparison of HERV/MSRV expression between
different therapy groups in MS, and other studies are
needed to confirm such findings.
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